• Cristiano Huscher, Giampaolo Perri, Gianni Lazzarin, Giovanni Marchegiani, Giuseppe Malleo, Roberto Salvia, and Claudio Bassi.
• Department of Oncologic Surgery, Robotic and new Technology, Policlinico Abano, Padova, Italy.
• Ann. Surg. 2022 Apr 1; 275 (4): e665-e668.

ObjectiveTo assess the feasibility and clinical utility of coronary artery stent (CAS) in securing pancreatico-jejunal anastomosis (PJ) and avoid stent displacement after pancreatoduodenectomy (PD).Summary Of Background DataExternalized trans-anastomotic stent (ETS) is a standard mitigation strategy for postoperative pancreatic fistula (POPF) in high-risk patients. However, major morbidity remains extremely elevated, especially in case of ETS malfunction due to displacement.MethodsA pilot series of 72 patients underwent PD and PJ with CAS positioning between January 2016 and December 2019. All patients were at high-risk for POPF (soft pancreatic texture; main pancreatic duct diameter ≤ 3 mm) and underwent a CT-scan at postoperative day 5 and 10 to assess the correct CAS positioning. Postoperative outcomes were analyzed, and displacement rates were compared with a cohort of 141 patients with the same high-risk characteristics, undergoing PD with PJ and externalized trans-anastomotic stent (ETS).ResultsNo CAS-related complications were registered in the study group. In particular, no CAS displacement was registered, compared to a 28% ETS malfunction (either displacement or occlusion). The POPF rate, major morbidity, and mortality were 11%, 6%, and 0% respectively.ConclusionsThe CAS positioning appears to be a feasible and safe mitigation strategy to secure PJ anastomosis after PD with high POPF risk avoiding stent displacement. Further validation and comparison with current standard of care is required in a prospective controlled setting.Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

25 keywords...

hide…